Halberd

Home>Halberd

About Halberd

This author has not yet filled in any details.
So far Halberd has created 11 blog entries.
Oct 19 2021

Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

By |2021-10-19T20:51:31-04:00October 19th, 2021|Press Releases|Comments Off on Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

Abstract Aims/hypothesis A subset of obese individuals remains insulin sensitive by mechanisms as yet unclear. The hypothesis that maintenance of normal subcutaneous (SC) adipogenesis accounts, at least partially, for this protective phenotype and whether it can be abrogated by chronic exposure to IL-6 was investigated. Methods Adipose tissue biopsies were collected from insulin-sensitive (IS) and ...

Oct 19 2021

Insulin Resistance Associated To Obesity: The Link TNF-Alpha

By |2021-10-19T20:43:06-04:00October 19th, 2021|Press Releases|Comments Off on Insulin Resistance Associated To Obesity: The Link TNF-Alpha

Iria Nieto-Vazquez, Sonia Fernández-Veledo, David K. Krämer,Rocio Vila-Bedmar, Lucia Garcia-Guerra & Margarita Lorenzo Abstract Adipose tissue secretes proteins which may influence insulin sensitivity. Among them, tumour necrosis factor (TNF)-alpha has been proposed as a link between obesity and insulin resistance because TNF-alpha is overexpressed in adipose tissue from obese animals and humans, and obese mice ...

Oct 19 2021

Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

By |2021-10-19T20:34:25-04:00October 19th, 2021|Press Releases|Comments Off on Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

SOURCE: https://news.mit.edu/2016/fat-fighting-nanoparticles-obesity-0502   "Researchers at MIT and Brigham and Women’s Hospital have developed nanoparticles that can deliver antiobesity drugs directly to fat tissue. Overweight mice treated with these nanoparticles lost 10 percent of their body weight over 25 days, without showing any negative side effects. The drugs work by transforming white adipose tissue, which is ...

Oct 19 2021

Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

By |2021-10-19T20:31:40-04:00October 19th, 2021|Press Releases|Comments Off on Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

Abstract Objective: We undertook this study to determine the relationship among -174G>C and 598G>A polymorphisms in the promoter region of interleukin-6, obesity, and metabolic abnormalities in subjects from central Mexico. Methods: Included in the study were 150 subjects who were not first-degree relatives of patients with diabetes and 106 blood samples from the general population. ...

Oct 19 2021

Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

By |2021-10-19T20:41:18-04:00October 19th, 2021|Press Releases|Comments Off on Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

Abstract Objective: To investigate the relationship between alpha 1-antitrypsin (A1AT), adiponectin, leptin, blood glucose, and insulin protein levels in human serum and obesity. Methods: Forty-eight subjects with normal blood glucose levels and average age of 32.4+/-5.1 years were enrolled in this study. The study took place in the Reproductive Center, The Second Hospital of Jilin University, Changchun, ...

Jan 28 2021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

By |2021-01-28T08:45:25-05:00January 28th, 2021|Featured, Investor News, News|0 Comments

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast   Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, ...

Jul 27 2020

Retired NFL Great Carl Eller Joins Halberd Corporation

By |2020-07-30T17:30:57-04:00July 27th, 2020|Featured, Investor News, News|0 Comments

Will Assist with Covid-19 Efforts and the Brain Jackson Center, PA, July 27, 2020 – Halberd Corp. (OTC PINK: "HALB") announced the appointment of Carl Eller, retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association as a consultant.  Mr. Eller’s expertise and contacts will be leveraged as part of ...

Jul 22 2020

Halberd Corporation CTO, Dr. Patricio Reyes, Presents Information at Virtual Event on Covid-19’s Effects on Neurological Functions

By |2020-07-30T12:19:33-04:00July 22nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 22, 2020 – Halberd Corporation (OTC Pink: HALB) announced their Chief Technical Officer and Head of Scientific Advisory Board, Dr. Patricio Reyes, presented A Community Information Session virtual event hosted yesterday by the Brain Injury Alliance of Arizona, on “Covid-19 & the Nervous System; Neurological Complications That Can Result”.  Dr. Reyes ...

Apr 8 2020

Premier Biomedical, Halberd and Gold River Agree to Work Jointly to Develop Premier’s Patented Extracorporeal Technology on COVID-19 Treatment And Proprietary Anti-Addiction PatchTM

By |2020-04-08T21:24:15-04:00April 8th, 2020|News|Comments Off on Premier Biomedical, Halberd and Gold River Agree to Work Jointly to Develop Premier’s Patented Extracorporeal Technology on COVID-19 Treatment And Proprietary Anti-Addiction PatchTM

Jackson Center, PA, April 8, 2020 – Premier Biomedical, Inc. (OTC-PINK: “BIEI“), Halberd Corporation (OTC-PINK: HALB) and Gold River Productions Inc. (OTC-PINK: GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction PatchTM. The Joint Venture on Covid-19 treatment starts with Dr. Mitchell ...

Apr 6 2020

Halberd Announces Agreement To Retire 192,000,000 Outstanding Common Shares

By |2020-04-06T18:24:14-04:00April 6th, 2020|News|Comments Off on Halberd Announces Agreement To Retire 192,000,000 Outstanding Common Shares

Halberd announces agreement to retire 192,000,000 outstanding common shares and acquisition/joint venture to be announced, in detail, this week. Lake Charles, Louisiana -- April 3, 2020 - Halberd Corporation (PINKSHEETS: HALB) announces that it has reached an agreement with shareholders holding 192,000,000 shares of the 482,838,125 reported as currently outstanding. Those shares will be returned to ...

Go to Top